Pacific Biosciences of California Inc
NASDAQ:PACB
Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 728 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The firm has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include Sequel, Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together can sequence up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together conduct, monitor, and analyze single molecule biochemical reactions in real time. The firm's Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 728 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The firm has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include Sequel, Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together can sequence up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together conduct, monitor, and analyze single molecule biochemical reactions in real time. The firm's Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.
Revenue Beat: PacBio reported Q4 revenue of $44.6 million, up 14% year-over-year and 16% sequentially, surpassing expectations.
Consumables Strength: Record consumables revenue drove growth and higher gross margins, with 15% YoY growth in Q4 and 55% annual growth in the clinical segment.
Guidance Raised: 2026 revenue is expected between $165 million and $180 million, indicating about 8% growth at the midpoint, driven primarily by consumables.
Gross Margin Expansion: Non-GAAP gross margin improved to 40% in Q4 and for the full year, up from 33% in 2024, with further improvements expected in 2026.
Cost Discipline: Operating expenses were cut by 18% YoY in Q4, reflecting restructuring and a focus on long-read sequencing.
SPRQ-Nx Launch: The new SPRQ-Nx chemistry promises to lower per-genome costs below $300 and is set for broader launch in 2026, expected to drive utilization and margins higher.
Regional Growth: EMEA saw 45% revenue growth in Q4, driven by clinical adoption, while Americas and APAC grew more modestly.
Short-Read Divestiture: The sale of short-read assets for $48 million strengthens the balance sheet and sharpens focus on long-read platforms.
